CBI Court Discharges Former CDSCO Official in 2022 Biocon Biologics Bribery Case
NiveshIQ
NSE: BIOCON · Healthcare
Biocon Ltd.
₹354.70▲ ₹2.90 (+0.82%)
Price Chart · Daily closes
1Y
6M
3M
1M
1W
1D
⚡ Intelligence Signals
5 active
🟢 Bullish Earnings Catalyst
📊 RS Laggard (5D)
🔄 Sector Sweep
⚡ Signals Aligned
📉 Pullback
NiveshIQ has detected 5 active signals on BIOCON. Sign up free to see what each signal means and how it affects the stock.
Unlock signals — freeExpected Move
1D / 1W / 1M range derived from news, fundamentals & technicals
1 Day
±1.8%
1 Week
±4.2%
1 Month
±9.6%
Confidence Score
Based on historical directional & magnitude accuracy for this stock
74
/ 100
About Biocon Ltd.
Biocon Limited is a leading Indian biopharma company that manufactures generic formulations, active pharmaceutical ingredients (APIs), and biosimilars across cardiovascular, anti‑diabetic, oncology, and immunology therapeutic areas, and offers contract research, development and manufacturing services (CRDMO) to pharma, biotech, and other industries. In FY2026, the company reported revenue of ₹17,321 cr and net income of ₹495 cr, reflecting a 10 % Q1 revenue growth into October. Biocon’s biosimilars portfolio includes oncology and diabetes products, while its generics segment covers a broad spectrum of cardiovascular and CNS molecules. The firm’s competitive edge stems from its integrated R&D and manufacturing capabilities, strong domestic presence, and expanding international footprint in
Financial Highlights
| Metric | FY24 | FY25 | FY26 |
|---|---|---|---|
| Revenue | ₹14,756 Cr +32.05% | ₹15,262 Cr +3.43% | ₹16,927 Cr +10.91% |
| EBITDA Margin | 22.36% | 20.75% | 20.41% |
| Net Profit | ₹1,022 Cr +120.99% | ₹1,013 Cr -0.90% | ₹385.60 Cr -61.95% |
| EPS | ₹8.55 | ₹8.46 | ₹2.82 |
Annual figures in Indian Rupees (Crores). Source: company filings (NSE).
Recent News
CBI Court Discharges Former CDSCO Official in 2022 Biocon Biologics Bribery Case
Failure is temporary, but giving up is final: Biocon’s Kiran Mazumdar-Shaw’s advice to executives
🔒
+ 3 more stories about Biocon Ltd.
Full news feed with AI impact summaries, synced in real time.
Sign up free — it's instantStrategic Outlook
- Q1FY27 results: revenue ₹4, 336 Cr, PAT ₹137 Cr, EPS ₹0.87, EBITDA margin 20.8%. Growth context: revenue QoQ -4.0%, PAT QoQ +1133.5%. Street verdict: miss, revenue surprise -3.5%, PAT surprise -16.0%.
Recent corporate activity highlights product launches, approvals, and therapy-mix improvement and new product launches a...
FY26 (last completed FY): revenue ₹16, 927 Cr, PAT ₹772 Cr, EBITDA margin 22.4%, EPS ₹2.82. Street consensus for FY27e: ...
🔒
+ 3 more outlook points
Growth drivers, key risks, and upcoming catalysts — unlocked free.
Sign up free — it's instantMore Healthcare stocks
Everything you unlock with a free account
⚡Intelligence Signals — AI-detected patterns across news, earnings & technicals
📈Price Chart — 1D to 1Y daily closes for BIOCON
🎯Expected Move — 1D / 1W / 1M range from news, fundamentals & technicals
🧠Confidence Score — Historical directional & magnitude accuracy for this stock
🎙Analyst Target Price — Consensus target with buy / hold / sell breakdown
📰Full News Feed — All stories synced in real time with AI impact summaries
🔭Strategic Outlook — Growth drivers, risks & upcoming catalysts
📊Watchlist & Portfolio — Track BIOCON alongside your other holdings
Unlock full BIOCON research — free
No credit card · No trial · Always free to start
Frequently Asked Questions
What AI signals does NiveshIQ provide for Biocon Ltd.?
NiveshIQ detects active intelligence signals for Biocon Ltd. (BIOCON) — including earnings catalysts, relative strength patterns, sector sweeps, and pullback setups. It also shows an Expected Move (1D/1W/1M range based on news, fundamentals and technicals) and a Confidence Score based on historical directional and magnitude accuracy. These are exclusive to NiveshIQ.
What are the key financials for Biocon Ltd.?
Biocon Ltd. operates in the Healthcare sector with a market capitalisation of ₹6,132,408.0L Cr. Revenue, net profit, EPS and EBITDA margins across the last three annual periods are shown above, sourced from BSE filings.
Does NiveshIQ provide investment advice?
No. NiveshIQ provides educational market intelligence and research context, not investment advice or buy/sell recommendations.